Cover Image

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Hyejung Jung, Aya A. Mitani, M. Ishrat Husain, Clement Ma
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Statistics in Medicine
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Statistical Inference for a Two‐Stage Adaptive Seamless Design Using Different Binary Endpoints
by: Ryota Ishii, et al.
Published: (2025)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
by: Jingya Gao, et al.
Published: (2024)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
by: Xinran Huang, et al.
Published: (2024)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
by: Daniel Backenroth, et al.
Published: (2026)

A Comparison of Two Methods for Adaptive Multi‐Arm Two‐Stage Design
by: Cyrus Mehta, et al.
Published: (2025)

Two‐Stage Double‐Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region
by: Jiashan He, et al.
Published: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
by: Yuwei Cheng, et al.
Published: (2026)

A Note on “A Comparison of Two Methods for Adaptive Multi‐Arm Two‐Stage Design”
by: Silke Jörgens, et al.
Published: (2026)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
by: Alessandra Serra, et al.
Published: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
by: Gi‐Ming Wang, et al.
Published: (2026)

Sequential Parallel Comparison Design for Assessing Induction, Maintenance, Long‐Term, and Other Treatment Effects on a Binary Endpoint
by: Hui Quan, et al.
Published: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
by: Moka Komaki, et al.
Published: (2026)

Two‐Stage Drop‐the‐Losers Design for the Selection of Effective Treatments and Estimating Their Average Worth
by: Yogesh Katariya, et al.
Published: (2025)

Semiparametric Inference for a Two‐Phase Failure‐Time‐Auxiliary‐Dependent Sampling Design
by: Xu Cao, et al.
Published: (2025)

A Modification to Two‐Stage Least Squares With Genetic Applications
by: Lei Fang, et al.
Published: (2025)

A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin
by: Guangyong Zou, et al.
Published: (2024)

Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches
by: Xiaotian Chen, et al.
Published: (2025)

Futility Monitoring in Clinical Trials
by: Ana M. Ortega‐Villa, et al.
Published: (2025)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
by: Yuan Li, et al.
Published: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
by: Adrien Ollier, et al.
Published: (2025)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
by: Kendra Davis‐Plourde, et al.
Published: (2025)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
by: Chloe E. Falke, et al.
Published: (2025)

A Partially Randomized Patient Preference, Sequential, Multiple‐Assignment, Randomized Trial Design Analyzed via Weighted and Replicated Frequentist and Bayesian Methods
by: Marianthie Wank, et al.
Published: (2024)

Correction for Participation Bias in Nonprobability Samples Using Multiple Reference Surveys
by: Victoria Landsman, et al.
Published: (2026)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
by: Cheng‐Han Yang, et al.
Published: (2026)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
by: Daniel E. Schwartz, et al.
Published: (2026)

Matching‐Assisted Power Prior for Incorporating Real‐World Data in Randomized Clinical Trial Analysis
by: Ruoyuan Qian, et al.
Published: (2025)

Powerful Test of Heterogeneity in Two‐Sample Summary‐Data Mendelian Randomization
by: Kai Wang, et al.
Published: (2024)

A Modified Debiased Inverse‐Variance Weighted Estimator in Two‐Sample Summary‐Data Mendelian Randomization
by: Youpeng Su, et al.
Published: (2024)

Variability in Causal Effects and Noncompliance in a Multisite Trial: A Bivariate Hierarchical Generalized Random Coefficients Model for a Binary Outcome
by: Xinxin Sun, et al.
Published: (2024)

Bayesian Response‐Adaptive Randomization for Cluster Randomized Controlled Trials
by: Yunyi Liu, et al.
Published: (2026)

Adaptive Seamless Phase II / III Randomization Test Considering Treatment Group Selection Based on Short–Term Binary Outcomes
by: Funato Sato, et al.
Published: (2026)

Model‐Robust Standardization in Cluster‐Randomized Trials
by: Fan Li, et al.
Published: (2025)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
by: Rebecca B. Silva, et al.
Published: (2024)

Doubly Robust Estimators of the Restricted Mean Time in Favor Estimands in Individual‐ and Cluster‐Randomized Trials
by: Xi Fang, et al.
Published: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
by: Yichen Yan, et al.
Published: (2025)

Handling Missing Outcome Data in Cluster Randomized Trials With Both Individual‐ and Cluster‐Level Dropout
by: Analissa Avila, et al.
Published: (2025)

Correction to “Model‐Robust Standardization in Cluster‐Randomized Trials”
Published: (2026)

On Anticipation Effect in Stepped Wedge Cluster Randomized Trials
by: Hao Wang, et al.
Published: (2026)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
by: Ethan Ashby, et al.
Published: (2025)